Chinese biotech developing antibody and antibody-drug-conjugate (ADC) therapies for cancer.
Chinese biotech developing antibody and antibody-drug-conjugate (ADC) therapies for cancer.
In one line: A Chinese ADC-focused biotech, akin to a smaller Seagen.
Moat: narrow (IP / patents, process know-how). Proprietary ADC linker/payload technology platform.
Headquarters: Shanghai, China · Founded: 2017 · Employees: 1,325
Size Mabwell (Shanghai) Bioscience (2493.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.20B, the 532nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$17.67 on 18 Nov 2026.
Performance Over six months the shares fell 29.1%, against -17.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 20.9% over the last twelve months (peer median +3.1%); the operating margin is -126.8% (peer median 0.8%).
Valuation It trades at 13.6× enterprise value to sales against a peer median of 7.6× (4th most expensive of 18).
Capital Return on invested capital runs 30.5 points below its cost of capital (5.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$822M | HK$717M | HK$215M | HK$140M | HK$32.2M |
| Revenue growth | — | +233% | +54% | +334% | — |
| Gross profit | HK$681M | HK$419M | HK$42.9M | HK$17.5M | -HK$79.3M |
| EBITDA | n/a | -HK$729M | -HK$959M | -HK$1.08B | -HK$1.05B |
| Net income | -HK$1.19B | -HK$1.05B | -HK$1.13B | -HK$1.16B | -HK$1.11B |
| Free cash flow | -HK$1.19B | -HK$484M | -HK$1.39B | -HK$1.41B | -HK$1.47B |
| Capital expenditure | HK$123M | HK$171M | HK$358M | HK$552M | HK$634M |
| Total debt | HK$4.32B | HK$3.31B | HK$2.36B | HK$1.42B | HK$870M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience 2493.HK | $1.20B | -29% | +21% | -127% | 13.6× | n/a |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
| RemeGen 9995.HK | $6.07B | -28% | +293% | 61% | 4.4× | -6.8% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2493.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.0% | -5.1% | 8th lowest of 21 |
| 6-month return | -29.1% | -17.3% | 7th lowest of 21 |
| Distance from 52-week high | -43.8% | -39.3% | 8th lowest of 21 |
| Revenue growth (TTM) | +20.9% | +3.1% | 7th highest of 18 |
| Operating margin | -126.8% | 0.8% | 4th lowest of 18 |
| EV / Sales | 13.6× | 7.6× | 4th most expensive of 18 |
| ROIC minus cost of capital | -30.5 pp | -5.1 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |